Media headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aclaris Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.809659321193 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of analysts have commented on the company. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. Guggenheim reissued a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. JMP Securities reissued an “outperform” rating and set a $39.00 price objective on shares of Aclaris Therapeutics in a report on Friday, September 8th. Finally, Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Aclaris Therapeutics currently has an average rating of “Buy” and a consensus price target of $39.20.

Shares of Aclaris Therapeutics (NASDAQ ACRS) traded up 2.15% during trading on Monday, hitting $25.22. The stock had a trading volume of 118,210 shares. Aclaris Therapeutics has a 52-week low of $20.15 and a 52-week high of $33.25. The stock has a 50 day moving average of $26.21 and a 200 day moving average of $26.71. The firm’s market cap is $674.28 million.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. On average, equities analysts anticipate that Aclaris Therapeutics will post ($3.10) EPS for the current year.

In other news, Director Andrew N. Schiff purchased 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The stock was bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 16.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/30/aclaris-therapeutics-acrs-receives-media-sentiment-rating-of-0-14.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.